In a recent work, we showed that autoantibodies against AT1 receptors (AT1-AA; AT1 receptor agonists) and for ACE2 (ACE2-AA, ACE2 antagonists) are associated with severity of COVID-19 outcome and could be used as an index of probable progression of COVID-19 toward severity (16), which was also observed in other recent studies (14, 15). The gene discussed is ACE2; the disease is COVID-19.